| SYMPOSIUM |
|
| Year : 2007 | Volume
: 23
| Issue : 1 | Page : 55-60 |
|
|
Chemotherapy for hormone-resistant prostate cancer: Where are we today?
Tomas Buchler, Stephen J Harland
Department of Oncology, University College London Hospital, London, United Kingdom
Correspondence Address:
Stephen J Harland
The Department of Oncology, 1st Floor Central, UCLH, 250 Euston Road, London, NW1 2PG
United Kingdom
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0970-1591.30269
|
|
|
Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC patients. Docetaxel is now considered the best available chemotherapy for prostate cancer progressing on first-line hormonal treatment. Other cytotoxics including mitoxantrone, anthracyclines, vinorelbin and vinblastine can alleviate symptoms and improve progression-free survival in HRPC without affecting overall survival. The survival benefit from chemotherapy seen in randomized studies has been small or nonexistent. Results of a recent trial suggest that the survival benefit may have been underestimated as a result of crossover from the less active to the active arm. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
